Navigation Links
Roche/Chugai's Bitopertin Will Garner Nearly $1.5 Billion in Major-Market Sales in 2022 as the First Approved Treatment for Negative Symptoms in Schizophrenia
Date:8/22/2013

BURLINGTON, Mass., Aug. 22, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Chugai's glycine transporter-1 inhibitor bitopertin is poised to be the first approved treatment to address negative symptoms in schizophrenia following its forecasted launch in the United States and Europe (France, Germany, Italy, Spain and United Kingdom) in 2016 and in Japan in 2017. As a first-in-class agent for the treatment of these prominent yet underserved symptoms of schizophrenia, Decision Resources expects that bitopertin will garner nearly $1.5 billion in major-market sales in 2022.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

"Treatments for negative symptoms, such as abnormalities in emotional expression and social interaction, is one of the top unmet needs in schizophrenia because—although nearly two-thirds of patients experience notable negative symptoms—currently available antipsychotics have not proven efficacious and reliable in treating such symptoms," said Decision Resources Senior Business Insights Analyst Anne-Elise Tobin, Ph.D. "Bitopertin has engendered enthusiasm from interviewed key opinion leaders, who say its novel mechanism of action will be beneficial as an adjunctive therapy to current antipsychotics. Because bitopertin will be used adjunctively and thus will not compete directly with other currently available therapies, it will contribute to market growth over the forecast period."

The Pharmacor advisory service entitled Schizophrenia also finds that the launch of depot formulations of two atypical antipsychotics—which are currently available in oral form—will lead to an overall increase in the use of depot formulations across the major markets under study. In particular, Otsuka/Lundbeck's once-monthly Abilify Maintena will provide a more-tolerable option than current depot products, and Janssen's paliperidone palmitate three-month formulation will offer substantial compliance and administration advantages over currently available once-monthly or twice-monthly depots. Together, these two agents are expected to capture major-market sales of nearly $1.8 billion in 2022.

The report finds that the schizophrenia market will grow from $6.3 billion in 2012 to $8.0 billion in 2022, owing to the launch of multiple premium-priced emerging therapies, including bitopertin, Abilify Maintena and paliperidone palmitate three-month depot. Uptake of emerging products will offset the impact of expanding generic competition across the major markets through 2022, including that from three of the four top patient-share leaders in the schizophrenia market, Eli Lilly's olanzapine (Zyprexa, generics), Bristol Myers-Squibb/Otsuka's Abilify and AstraZeneca/Astellas's quetiapine (Seroquel, generics).

In light of a growing generics presence, emerging agents for the treatment of schizophrenia will increasingly be forced to compete with low-cost alternatives of current products and the entrance of multiple new antipsychotics into this crowded market will require emerging therapies to adequately differentiate themselves from their competitors to ensure uptake and to obtain favorable reimbursement status.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Survey Reveals How Patients Choose Their Pharmacy; AccentHealth Garners Consumer Insights from the Waiting Room
2. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
3. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
4. Cardinal Health Supports Future Pharmacists With Nearly $1 Million In Scholarships
5. Zarbees Partners with K.I.D.S. by Donating Nearly 23,000 Bottles of All-Natural Cough Syrup to Underserved Families Across the Globe
6. ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children
7. Global Market for Disposable Medical Supplies To Reach Nearly $200 Billion in 2016
8. Nearly Half of Children Under 2 Years of Age Receive Some Vaccinations Late
9. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
10. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
11. Nearly 30 Percent of Women Fail to Pick Up New Prescriptions for Osteoporosis, Kaiser Permanente Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , Tenn. and DALLAS , April ... EndoStim, Inc., announced that the first patients in ... the EndoStim device in the Lower Esophageal Sphincter Stimulation ... a minimally-invasive implantable device designed to provide long-term reflux ... neurostimulation. GERD affects nearly 65 million people ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... 2017 , ... Veteran Theresa James awoke to the sound of her newly ... “Healing Tears,” James depicts every parent’s worst nightmare, when her three children were violently ... and situations throughout my divorce,” James said. “After the death of my children, I ...
(Date:4/24/2017)... ... ... My T Chai, a South African company that creates a number of ... a popular website specializing in sales of nutritional products. , Chai tea is ... It spread across Asia and Africa quickly, and today recipes vary from region to ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to ... approximately 25,000 of them will be malignant.(1) As research into precision medicine continues, ... healthcare model in the diagnosis and treatment of brain tumors. Healthcare facilities that ...
(Date:4/24/2017)... ... 2017 , ... As a former supermodel known for her timeless beauty, Joan ... single women is that she put all the words in her new book, "Manifest ... personal experiences and sparkling sense of humor have inspired her to write a book ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... shows that over the last decade, student well-being has seriously declined. "When disenfranchised ... of formal education, join the Islamic State to turn the historic multi-ethnic and ...
Breaking Medicine News(10 mins):